These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention

These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention
Ebos chief executive John Cullity says shareholders can expect more buying in Southeast Asia. (Image: Ebos)
Rebecca Stevenson
Listed healthcare and pet company Ebos says it sees investment potential in regenerative medicine firm Origin Biologics. Dual-listed Ebos reported its full-year result on Wednesday, with sales revenue exceeding A$13.2 billion (NZ$14.4b) for the first time. Ebos is known for its canny acquisitions and chief executive John Cullity said the company would continue its foray into Southeast Asia and medical devices, but there were also opportunities in the US. Ebos completed a major acquisition in 2022 when it purchased Lifehealthcare,...

More Markets

NZ sharemarket rises with gentailers leading
Markets Market close

NZ sharemarket rises with gentailers leading

Electricity gentailers pumped energy into the NZX.

Tom Raynel 09 May 2025
Steven Joyce to chair NZME
Markets

Steven Joyce to chair NZME

Tech expert Bowen Pan will also join, later on. 

Staff reporters 09 May 2025
NZME set to take on Trade Me for car sales
Markets

NZME set to take on Trade Me for car sales

Publicly listed NZME, owner of the NZ Herald and BusinessDesk, says it is exploring a new automotive digital classifieds platform, in a clear bid to take on Trade Me.Seeking to emulate the success of its property platform OneRoof, NZME said on Friday it had signed a memorandum of...

Staff reporters 09 May 2025
Bremworth getting back into synthetics
Primary Sector

Bremworth getting back into synthetics

Albeit in a small, but carefully curated, number of products.

Riley Kennedy 09 May 2025